Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of November 2021. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It is strictly a disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of notional ADSs |
| Instrument | American Depositary Shares (ADSs) |
| Price per ADS | $41.2900 |
| Volume | 1,211.138 ADSs |
| Transaction Date | November 22, 2021 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction within an executive savings plan and does not compare performance against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The transaction was executed within Dr. H. Barron's GSK Executive Supplemental Savings Plan account.
Investor Verification Points
- Verify the identity of the PDMR: Dr. H. Barron, Chief Scientific Officer and President, R&D.
- Confirm the transaction was an acquisition of notional ADSs, not a direct cash purchase of physical shares.
- Note the transaction date (November 22, 2021) and price ($41.29) for compliance and insider trading analysis.
- Recognize that this filing does not contain quarterly or annual financial results.